Retatrutide
ResearchA triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Investigational compound with some of the most dramatic weight loss data ever seen in clinical trials.
Weight ManagementMetabolic HealthGLP-1 Agonist
Half Life
~6 days
Time to Results
4-12 weeks
Administration
SubQ injection
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyOnce weekly
Cost$$$
🐾 Griffin Says...
The triple agonist is fascinating research territory. Early trials showed around 24% weight loss at highest doses, which is remarkable. Still investigational, so we're watching the safety data carefully. This is cutting-edge stuff.
Benefits
- Exceptional weight reduction (up to 24% in trials)
- Metabolic improvement
- Appetite suppression
- Potential cardiovascular benefits
Best For
- Advanced weight management research
- Metabolic health
Body Systems
MetabolicCardiovascularEndocrine
Mechanisms of Action
- Triple agonist: GLP-1, GIP, and glucagon receptors
- Enhanced fat oxidation via glucagon
- Appetite suppression
- Improves insulin sensitivity
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Very Common | Mild-Moderate |
| Vomiting | Common | Mild |
| Decreased appetite | Very Common | Mild |
Contraindications
Not yet FDA approved, use strictly for research, history of thyroid issues
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator